

HE Dr. Volda Lawrence  
Minister of Public Health  
Ministry of Public Health  
Brickdam, Stabroek  
Georgetown  
Republic of Guyana

28 May 2018

***Decision Letter: Revision of assigned doses for inactivated poliomyelitis vaccine (IPV) in 2018 and approval of Multi Age Cohort support for Human Papillomavirus vaccine***

Your Excellency,

I am writing to inform you that the assigned doses for the inactivated vaccine against poliomyelitis (IPV) in 2018 have been revised following the notification from PAHO Revolving Fund informing us that they will be making all the efforts to procure the necessary number of doses for full vaccine schedule despite the restricted supply environment.

We want to clarify that this does not guarantee that all countries receive all doses approved, hence the importance of following the recommendations of the Technical Advisory Group on Vaccine-Preventable Diseases of PAHO / WHO. But in the event that suppliers can meet the required dose amounts, GAVI is ensuring that the Revolving Fund has the necessary funding.

The prior approval for 2018 was for a total of 16,200 doses equivalent to US \$33,500. The new approval is for a total of 20,600 doses equivalent to US\$45,500. Please notices that the Annex B of this letter replaces the Annex A of the decision letter sent to the country dated November 22, 2017.

Additionally, I take the opportunity to inform you that Gavi has **approved** Guyana's request to expand Gavi support to include the 14 year old girls in 2018, subject to several conditions and requirements as specified in the Appendices to this letter.

The Appendices include the following important information:

Appendix A: Guyana Support for Human Papillomavirus Vaccine

Appendix B: Guyana Support for Inactivated Polio Vaccine (IPV)

Appendix C: Guyana Support for Injection Safety Devices

Please do not hesitate to contact my colleague Mr Ricard Lacort Monte, Senior Country Manager for Guyana, at [rlacort@gavi.org](mailto:rlacort@gavi.org) if you have any questions or concerns.

Sincerely yours,



Hind Khatib-Othman  
Managing Director, Country Programmes



cc: Minister of Finance  
Director of Planning, Ministry of Health  
EPI Manager, Ministry of Health  
WHO Country Representative  
WHO AMRO/PAHO  
UNICEF Country Representative  
UNICEF Regional Office  
UNICEF Programme Division

Decision Letter

Guyana - Support for Human Papillomavirus Vaccine (HPV)

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Guyana			
<b>2. Routine vaccines grant number:</b> 17-GUY-19b-X <b>Routine vaccine introduction grant:</b> 17-GUY-08f-Y <b>Multi age cohort vaccines grant number:</b> 18-GUY-19c-X <b>Multi age cohort operation costs grant number:</b> 18-GUY-19e-Y			
<b>3. Date of Decision Letter:</b> 28/05/2018			
<b>4. Date of the Partnership Framework Agreement:</b> 05/02/2015			
<b>5. Programme title:</b> New Vaccine Support (NVS), HPV Routine with multi age cohort in the year of introduction			
<b>6. Vaccine type:</b> Human Papilomavirus Vaccine			
<b>7. Requested product presentation and formulation of vaccine:</b> HPV Quadrivalent, 1 dose per vial, LIQUID			
<b>8. Programme duration<sup>1</sup>:</b> 2017 -2018			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)			
	<b>2017</b>	<b>2018</b>	<b>Total<sup>2</sup></b>
Programme Budget (Routine) (US\$)	49,500	0	49,500
Multi Age Cohort Support (US\$)	0	39,000	39000
<b>Total (\$US)</b>	<b>49,500</b>	<b>39,000</b>	<b>88,500</b>
<b>10. Vaccine introduction grant (in US\$):</b> The Vaccine introduction grant of US\$100,000 was disbursed on 10/05/2017			
<b>11. Operational support for Multi Age Cohort :</b>			
	<b>2018</b>		
<b>Grant amount (US\$)</b>	3,675		
<b>12. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>3</sup>			
<b>Type of supplies to be purchased with Gavi funds in each year (Routine)</b>	<b>2017</b>	<b>2018</b>	
Number of HPV vaccines doses			
<b>Annual Amounts (US\$)</b>	<b>49,500</b>		
<b>Type of supplies to be purchased with Gavi funds in each year (Multi Age Cohort)</b>	<b>2017</b>	<b>2018</b>	
Number of HPV vaccines doses		8,600	
<b>Annual Amounts (US\$)</b>		<b>39,000</b>	
<b>13. Procurement agency:</b> PAHO. The Country shall release its co-financing payments each year to PAHO.			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the amount that Gavi has approved.

**14. Self-procurement:** Not applicable.

**15. Co-financing obligations: Reference code: 17-GUY-19b-X-C**

According to the co-financing policy, the Country falls within the group Fully self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

**Routine**

Type of supplies to be purchased with Country funds each year	2017	2018
Number of vaccine doses	10,800	
Number of AD syringes	11,400	
Number of safety boxes	125	
Value of vaccine doses (US\$)	48,263	
<b>Total co-financing payments (US\$) (including freight)</b>	<b>50,000</b>	

**Reference code: 18-GUY-19c-X-C**

**Multi Age Cohort**

Type of supplies to be purchased with Country funds each year	2017	2018
Number of vaccine doses		8,600
Number of AD syringes		9,000
Number of safety boxes		100
Value of vaccine doses (US\$)		38,590
<b>Total co-financing payments (US\$) (including freight)</b>		<b>39,500</b>

**16. Additional reporting requirements:**

Additional reports	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May of each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Not applicable

**18. Other conditions:** Not applicable

**On behalf of Gavi**

Signed by,



Hind Khatib-Othman  
Managing Director, Country Programmes  
28 May 2018

**Decision Letter**  
**Guyana - Support for Inactivated Polio Vaccine (IPV)**

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Guyana			
<b>2. Grant number:</b> 18-GUY-25b-X 15-GUY-08h-Y			
<b>3. Date of Decision Letter:</b> 28/05/2018			
<b>4. Date of the Partnership Framework Agreement:</b> 05/02/2015			
<b>5. Programme title:</b> New Vaccine Support, IPV routine			
<b>6. Vaccine type:</b> Inactivated Polio Vaccine (IPV)			
<b>7. Requested product presentation and formulation of vaccine<sup>4</sup>:</b> Inactivated Polio Vaccine, 5 doses per vial, LIQUID			
<b>8. Programme duration<sup>5</sup>:</b> 2015 - 2018			
<b>9. Indicative Programme Budget:</b> (subject to the terms of the Partnership Framework Agreement) <i>Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	<b>2015-2017</b>	<b>2018</b>	<b>Total<sup>6</sup></b>
Routine Programme (US\$)	113,000 <sup>7</sup>	45,500	158,500
<b>Total Budget (US\$)</b>	<b>113,000</b>	<b>45,500</b>	<b>158,500</b>
<b>10. Vaccine introduction grant:</b> Not applicable. The Vaccine Introduction Grant of US\$ 100,000 was disbursed on 16 September 2015.			
<b>11. Product switch grant:</b> Not applicable.			
<b>12. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>8</sup>			
Number of vaccines to be purchased with Gavi funds	2015-2017	2018	
IPV Routine Programme (doses)		20,600	
<b>Annual Amounts (US\$)</b>	<b>113,000</b>	<b>45,500</b>	
<b>13. Procurement agency:</b> PAHO. The Country shall release its co-financing payments each year to PAHO.			
<b>14. Self-procurement:</b> Not applicable.			
<b>15. Co-financing obligations:</b> Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Guyana is encouraged to contribute to vaccine and/or supply costs for IPV.			
<b>16. Operational support for catch-up campaigns:</b> Not applicable			
<b>17. Additional reporting requirements:</b>			
<b>Additional reports</b>			<b>Due dates</b>

<sup>4</sup> Please refer to section 18 for additional information on IPV presentation.

<sup>5</sup> This is the entire duration of the Programme.

<sup>6</sup> This is the total amount endorsed by Gavi for 2015 to 2018.

<sup>7</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>8</sup> This is the amount that Gavi has approved.

To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat


**18. Financial clarifications:** Not applicable.

**19. Other conditions:** Not applicable.

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

Signed by,

**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes  
28 May 2018

**Decision Letter**  
**Guyana -Support for Injection Safety Devices**

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Guyana			
<b>2. Grant number:</b> 17-GUY-32a-X; 18-GUY-32a-X ;			
<b>3. Date of Decision Letter:</b> 28/05/2018			
<b>4. Date of the Partnership Framework Agreement:</b> 05/02/2015			
<b>5. Programme title:</b> Injection safety devices <sup>9</sup>			
<b>6. Programme duration</b> <sup>10</sup> : 2017-2018			
<b>7. Programme Budget (indicative):</b> (subject to the terms of the partnership framework agreement)			
	<b>2017</b>	<b>2018</b>	<b>Total</b> <sup>11</sup>
<b>Programme Budget (US\$)</b>	2,000	1,500	<b>3,500</b>
<b>8. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>12</sup>			
<u>TOTAL</u> injection safety devices to be purchased with Gavi funds in each year	2017	2018	
Number of AD syringes		26,600	
Number of re-constitution syringes			
Number of safety boxes		300	
<b>Annual Amounts for injection safety devices for all Gavi vaccines (US\$)</b>	<b>2,000</b>	<b>1,500</b>	
<b>Injection safety devices to be purchased with Gavi funds in each year, <u>by type of support</u></b>			
<b>New Vaccine Support (NVS), Inactivated Polio Vaccine, 5 doses per vial, LIQUID, Routine</b>			<b>2018</b>
Number of AD syringes			17,600
Number of safety boxes			200
<b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>			<b>1,000</b>
<b>New Vaccine Support (NVS), HPV Multi Age Cohort Quadrivalent, 1 dose per vial, LIQUID</b>			<b>2018</b>
Number of AD syringes			9000
Number of safety boxes			100
<b>Annual Amounts for injection safety devices for Vaccine (US\$)</b>			<b>500</b>

<sup>9</sup> This does not include vaccines.

<sup>10</sup> This is the entire duration of the Programme.

<sup>11</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>12</sup> This is the amount that Gavi has approved.

- |  |
|--|
| <b>9. Procurement agency:</b> PAHO. The Country shall release its co-financing payments each year to PAHO.         |
| <b>10. Self-procurement:</b> Not applicable  |
| <b>11. Co-financing obligations:</b> Co-financing requirements are listed in the relevant vaccine Decision Letter. |

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
28 May 2018